

UNCLASSIFIED

AD NUMBER
ADB240902
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info; Aug 98 Other requests shall be referred to USAMRMC, Fort Detrick, MD 21702-5012
AUTHORITY
USAMRMC ltr, 28 Jul 2003

THIS PAGE IS UNCLASSIFIED

AD _____

AWARD NUMBER DAMD17-97-1-7260

TITLE: The Role of SHP1 as a Tumor Suppressor Gene in Human Mammary

PRINCIPAL INVESTIGATOR: Chuan Gao

CONTRACTING ORGANIZATION: University of Texas
M.D. Anderson Cancer Center
Houston, Texas 77030

REPORT DATE: August 1998

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5400

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Aug 98). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Contract Number: DAMD17-97-1-7260

Contractor: University of Texas/M.D. Anderson Cancer Center

Location of Limited Rights Data (Pages): 1-12

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Patricia M. Moore *12/23/95* *limited distribution*

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE August 1998	3. REPORT TYPE AND DATES COVERED Annual (1 Aug 97 - 31 Jul 98)	
4. TITLE AND SUBTITLE The Role of SHP1 as a Tumor Suppressor Gene in Human Mammary			5. FUNDING NUMBERS DAMD17-97-1-7260	
6. AUTHOR(S) Chuan Gao				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Texas M.D. Anderson Cancer Center Houston, Texas 77030			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5400			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES			19990115 089	
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, Aug 98). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) To investigate the possible involvement of SHP1 in human mammary tumorigenesis, SHP1 was stably transfected into a human breast cancer cell line MDA-MB231, which has very low endogenous SHP1 level compared to normal breast epithelium. While the over-expression of SHP1 did not lead to any significant change in the proliferation rate of these cells, it appeared to enhance their ability in anchorage-independent growth as well as their potential of tumorigenesis in nude mice. The over-expression of SHP1 changed neither the tyrosine phosphorylation status of overall cellular proteins or EGFR upon EGF stimulation in MDA-MB231 cells, nor the activation patterns of MAP kinases and AKT upon EGF and PDGF stimulation, respectively, in NIH3T3 cells. While more studies are necessary to further characterize the MDA-MB231 transfectants, such as their invasiveness, it has also been planned to study the involvement of each important domain of SHP1 in tumorigenesis with a series of SHP1 mutants generated in this laboratory.				
14. SUBJECT TERMS Breast Cancer SHP1 Protein tyrosine phosphatase			15. NUMBER OF PAGES 12	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Limited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

____ Where copyrighted material is quoted, permission has been obtained to use such material.

Cg Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Cg Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


____ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

Cg For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

Cg In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

Cg In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.


PI - Signature

J-25-98
Date

TABLE OF CONTENTS

Introduction.....	1
Results.....	3
Conclusions.....	6
Bibliography.....	7

INTRODUCTION

The regulation of cell proliferation and differentiation is mediated by a complex network of signal transduction pathways. Protein phosphorylation is an important mechanism which cells use to pass signals from the extracellular environment to the nucleus. Proteins can be phosphorylated on tyrosine residues, a process catalyzed by protein tyrosine kinases (PTKs), and in a reverse action, dephosphorylated by protein tyrosine phosphatases (PTPs). Aberrant protein tyrosine phosphorylation plays an essential role in tumorigenesis. The activation of PTKs commonly promotes cell proliferation, and most of the oncogenes identified to date are either PTKs, their regulators, or their target proteins. In contrast to PTKs, relatively less research has been focused on the role that PTPs may play in tumorigenesis, although the functions of PTPs, which catalytically reverse the phosphorylation process mediated by PTKs, could be just as important as those of PTKs in cell growth regulation.

Structurally, PTPs can be divided into two groups: the transmembrane receptor PTPs and the intracellular non-receptor PTPs (1). SHP1 (also called SHPTP1, HCP, PTP1C and PTPN6) is a member of the non-receptor, intracellular PTP subfamily. SHP1 was first identified as a *src*-homology 2 (SH2) domain-containing PTP (2, 3), besides its consensus tyrosine phosphatase domain. It is expressed at high levels in hematopoietic cell lineages and at relatively lower levels in normal epithelial cells (2, 4). Studies by different laboratories have demonstrated associations between the SH2 domains of SHP1 and phosphorylated tyrosine residues of a variety of receptor PTKs (5-7). The main function of SHP1 in hematopoietic cells is commonly thought to be downregulation of the proliferative signals via dephosphorylating, and, hence inactivating, receptor tyrosine kinases which transduce these signals.

The functions of SHP1 in non-hematopoietic cells, on the other hand, are less studied and therefore remain largely unclear. There have been published studies reporting both positive and negative effects of SHP1 on proliferative signaling in a number of non-hematopoietic cell lines(8-10). The first suggestion that SHP1 played a role in tumorigenesis came from the study of loss-of-function mutations in the SHP1 gene which naturally occur in motheaten (*me*) mice. Consistent with the commonly-accepted role of SHP1 as a negative regulator of proliferative signaling in hematopoietic cells, mice with these mutations show hyperproliferation of certain types of hematopoietic cells, and consequently suffer from severe combined immunodeficiency, as well as systemic autoimmunity. Infiltration of the hyperproliferating neutrophils and granulocytes in the skin leads to patchy alopecia, --the "motheaten" phenotype. The *me* phenotype results

from total loss of functional SHP1 protein due to a premature stop codon generated by a frame-shift deletion within the N-terminus SH2 domain (11, 12). Some surprising findings have led to the initial speculation that SHP1 may act as a tumor suppressor: although homozygous *me/me* mice develop aberrant hematopoiesis and profound autoimmune disease, which cause hemorrhagic pneumonitis and consequent death by the age of 4-6 weeks (13, 14), one *me/me* mouse developed a metastatic mammary adenocarcinoma prior to death at 3 weeks of age. In contrast, the heterozygous *me/+* mice, which have a much longer life span, show a 60% chance to develop breast tumors by the age of 18 months, with SHP1 still expressed in their normal breast tissues but no longer in the tumors. All these observations suggest the possibility that SHP1 plays a role in mammary tumorigenesis.

The putative involvement of SHP1 in human breast cancer has also been suggested by the following findings: 1) SHP1 can associate with, and dephosphorylate, some epidermal growth factor receptor (EGFR) PTK family members (2, 12, 14, 15). The EGFR family, including EGFR and the products of the *erbB2/neu*, *erbB3* and *erbB4* genes, is a family of closely related growth factor receptor protein tyrosine kinases. These receptor PTKs strongly influence cellular growth through the ligand-stimulated tyrosine phosphorylation of intracellular substrates. The amplification of these genes has been observed in a variety of human carcinomas (16), and the amplification or overexpression of *erbB2/neu* is particularly associated with a poor prognosis in at least a third of human breast and ovarian cancers (17, 18); 2) SHP1 can associate with *src* family PTKs. The *src* family includes nine members: *src*, *yes*, *fyn*, *lyn*, *lck*, *fgr*, *hck*, *blk* and *yrk*, that are intracellular PTKs involved in signal transduction pathways. Some of these PTKs are also implicated in oncogenic transformation in human mammary tumorigenesis (19, 20); In several studies, it has been shown that the activation of the EGFR family PTKs can cause an increase in Src PTK activity, whereas the inhibition of Src kinase activity can suppress the proliferative response mediated by the EGFR family PTKs (20-22). SHP1 is known to be a substrate for v-Src PTK; the overexpression of SHP1 can lead to decreased v-Src PTK activity and inhibited proliferation in fibroblasts (8). Although the exact nature and mechanism of the regulation of the EGFR family and of the *src* family PTK activity are yet to be understood, the involvement and significance of SHP1 in such processes, and therefore in tumorigenesis, have been strongly suggested.

Several lines of evidence support the contention that SHP1 plays a role in the process of tyrosine phosphorylation-mediated signaling in epithelial cells and during human mammary tumorigenesis. This study is focused on the potential role of SHP1 in human mammary tumorigenesis and the mechanism by which SHP1 may function as a regulator of signaling in breast epithelium.

RESULTS

1. The expression and activity of SHP1 in human breast cancer cells.

The expression levels of SHP1 in a series of human breast cancer cell lines were determined by Western blotting analysis. In comparison to normal human breast epithelium and two nontumorigenic human breast epithelial cell lines, MCF 10A and 10F, most of the human breast cancer cell lines showed normal or slightly elevated levels of SHP1 expression, with the exceptions of the cell lines MDA-MB231 and MDA-MB435, which showed very low or undetectable levels of SHP1 expression, respectively.

The activity levels of SHP1 in these human breast cancer cell lines were determined in assays using PNPP as substrate following immunoprecipitation with anti-SHP1 antibody. The assay results showed that the levels of SHP1 activity in these cell lines corresponded with their levels of expression. No altered specific activity was found.

2. Stable over-expression of SHP1 in the MDA-MB231 human breast cancer cells.

SHP1, or an enzymatically inactive form of SHP1 was transfected into both the MDA-MB231 and MDA-MB435 cells using LipofectAmine reagent. Upon selection of stably transfected clones with G418, only the MDA-MB231 cells yielded numerous clones with SHP1 expression, whereas transfection of the MDA-MB435 cells failed to yield any clones with increased SHP1 expression in several attempts.

3. The effects of SHP1 when stably over-expressed in the MDA-MB231 cells.

A. The effects of SHP1 over-expression on proliferation rate.

The proliferation rates of the MDA-MB231 clones stably transfected with either vector alone, SHP1, or the inactive form of SHP1 were determined by the means of MTT assays. The results showed no significant difference in growth rates among all clones.

B. The effects of SHP1 over-expression on anchorage-independent growth.

The ability of the MDA-MB231 clones to grow in an anchorage-independent manner was determined by soft agar assays. The results showed that the over-expression of enzymatically active SHP1 in the MDA-

MB231 cells led to increased anchorage-independent growth, whereas the vector or the enzymatically inactive form of SHP1 failed to do so.

C. The effects of SHP1 over-expression on tumorigenicity in nude mice.

The tumorigenicity of the MDA-MB231 clones was determined in nude mice by injections of the cells in the mammary fat pad. The sizes of the tumors were measured over a period of two months. The results showed that only enzymatically active SHP1 rendered the cells increased tumorigenicity, while neither the vector nor the inactive form of SHP1 had any clear effects.

D. The effects of SHP1 over-expression on protein tyrosine phosphorylation in transfected MDA-MB231 cells upon EGF stimulation.

The changes in protein tyrosine phosphorylation status upon EGF stimulation in various MDA-MB231 clones transfected with either vector, SHP1, or the inactive form of SHP1 were determined by Western blotting analysis using anti-phosphotyrosine antibody. The results showed no significant changes in the overall protein tyrosine phosphorylation level or EGFR tyrosine phosphorylation level upon EGF stimulation in all three types of clones, with various EGF concentrations and at different time points.

4. The effects of SHP1 when transiently over-expressed in NIH3T3 cells.

In an attempt to understand the role of SHP1 may play in signal transduction pathways, the possible effects of SHP1 on MAP kinase activation and AKT kinase activation were studied in transient transfection assays. These assays were performed in NIH3T3 cells due to the following reasons: 1. In the MDA-MB231 cells MAP kinases were constitutively activated whereas AKT failed to become activated upon stimulation, thus the clones could not be used in these studies. 2. NIH3T3 cells had undetectable level of endogenous SHP1 expression and could be more efficiently transfected.

A. The effects of SHP1 over-expression on MAP kinase activation.

NIH3T3 cells were transiently transfected with a plasmid containing HA-tagged ERK2, along with either the vector, SHP1, or the inactive form of SHP1, four times the amount of the HA-ERK2 plasmid. Upon EGF stimulation, HA-ERK2, presumably only expressed in cells also expressing the co-transfected second plasmid, was immunoprecipitated with anti-HA antibody and its activation determined by Western

blotting analysis using an antibody specifically recognizes the activated MAPKs. The results showed no significant effects on ERK2 activation from SHP1 over-expression when the cells were stimulated with EGF at various concentrations.

B. The effects of SHP1 over-expression on AKT activation.

NIH3T3 cells were transiently transfected with a plasmid containing HA-tagged AKT, along with either the vector, SHP1, or the inactive form of SHP1, four times the amount of the HA-AKT plasmid. Upon PDGF stimulation, HA-AKT, presumably only expressed in cells also expressing the co-transfected second plasmid, was immunoprecipitated with anti-HA antibody and its activation determined by Western blotting analysis using an antibody specifically recognizes the activated AKT. The results showed no significant effects on AKT activation from SHP1 over-expression when the cells were stimulated with PDGF at various concentrations.

CONCLUSIONS

- 1. In the MDA-MB231 human breast cancer cells, the over-expression of SHP1 did not alter cell proliferation rate.**
- 2. In the MDA-MB231 cells, the over-expression of SHP1 resulted in increased anchorage-independent growth.**
- 3. In the MDA-MB231 cells, the over-expression of SHP1 resulted in increased tumorigenicity in nude mice.**
- 4. In the MDA-MB231 cells, the over-expression of SHP1 did not alter the tyrosine phosphorylation status of overall cellular proteins or EGFR upon EGF stimulation.**
- 5. In NIH3T3 cells, the over-expression of SHP1 did not alter the pattern of ERK2 activation upon EGF stimulation.**
- 6. In NIH3T3 cells, the over-expression of SHP1 did not alter the pattern of AKT activation upon PDGF stimulation.**

BIBLIOGRAPHY

1. Fischer EH, Charbonneau H and Tonks NK: Protein tyrosine phosphatases: a diverse family of intracellular and transmembrane enzymes. *Science* 253:401-406, 1991.
2. Shen S, Bastien L, Posner B and Chretien P: A protein-tyrosine phosphatase with sequence similarity to the SH2 domain of the protein-PTKs. *Nature* 532:736-739, 1991.
3. Yi T, Cleveland JL and Ihle JN: Identification of novel protein tyrosine phosphatases of hematopoietic cells by PCR amplification. *Blood* 78:2222-2228, 1991.
4. Yi T, Cleveland JL and Ihle JN: Protein tyrosine phosphatase containing SH2 domains: Characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-13. *Mol. Cell. Biol.* 12:836-846, 1992.
5. Yi T and Ihle JN: Association of hematopoietic cell phosphatase with c-Kit after stimulation with c-Kit ligand. *Mol. Cell. Biol.* 13:3350-3358, 1993.
6. Yi T, Mui ALF, Krystal G and Ihle JN: Hematopoietic cell phosphatase associates with the interleukin 3 (IL-3) receptor B chain and downregulates IL-3-induced tyrosine phosphorylation and mitogenesis. *Mol. Cell. Biol.* 13:7577-7686, 1993.
7. Yi T, Zhang J, Miura O and Ihle JN: Hematopoietic cell phosphatase associates with erythropoietin (Epo) receptor after Epo-induced receptor tyrosine phosphorylation: identification of potential binding sites. *Blood* 85:87-95, 1995.
8. Matazaki T, Uchida T, Fujioka Y and Kasuga M: Src kinase tyrosine phosphorylates SHP1, a protein tyrosine phosphatase containing Src homology-2 domains that down-regulates cell proliferation. *Biochem. Res. Commun.* 204:874-881, 1994.
9. Su L, Zhao Z, Bouchard P, Banville D, Fischer EH, Krebs EG and Shen S-H: Positive effect of overexpressed protein-tyrosine phosphatase PTP1C on mitogen-activated signaling in 293 cells. *J. Biol. Chem.* 271:10385-10390, 1996.
10. You M and Zhao Z: Positive effects of SH2 domain-containing tyrosine phosphatase SHP-1 on epidermal growth factor- and interferon- γ -stimulated activation of STAT transcription factors in Hela cells. *J. Biol. Chem.* 272: 23376-23381, 1997.

11. Tsui H, Siminovitch K, De Souza L and Tsui F: Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. *Nature Genet. cs* 4:124-129, 1993.
12. Kozloeski M, Mlinaric-Rascan I, Feng G, Shen R, Pawson T and Siminovitch K: Expression and catalytic activity for the tyrosine phosphatase SHP1 is severely impaired in motheaten and viable motheaten mice. *J Exp Med* 178:2157-2163, 1993.
13. Shultz L and Green M: Motheaten, an immunodeficient mutant of the mouse. II. Depressed immune competence and elevated serum immunoglobulins. *J. Immunol.* 116:936-943, 1976.
14. Vogle W, Lammers R, Huang J and Ullrich A: Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation. *Science* 259:1611-1614.
15. Tomic S, Greiser U, Lammers R, Kharitononkov A, Imyanitov E, Ullrich A and Bohmer F-D: Association of SH2 domain protein tyrosine phosphatases with the epidermal growth factor receptor in human tumor cells. *J. Biol. Chem.* 270:21277-21284, 1995.
16. Prigent SA and Lemoine NR: The type 1 (EGFR-related) family of growth factor receptors and their ligands. *Prog. Growth Factor Res.* 4:1-24, 1992.
17. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 235:177-182, 1987.
18. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science* 244:707-712, 1989.
19. Brickell PM: The p60c-src family of protein-tyrosine kinases: structure, regulation, and function. *Critical. Rev. in Onco.* 3:401-446, 1992.
20. Muthuswamy S and Muller W: Activation of the src family of tyrosine kinases activity in mammary tumorigenesis. *Adv. Cancer Res.* 64:111-123, 1994.
21. Muthuswamy S, Siegel P, Dankort D, Webster M and Muller W: Mammary tumors expressing the neu proto-oncogene possess elevated c-src tyrosine kinase activity. *Mol. Cell. Biol.* 64:111-123, 1994.
22. Siegel P, Dankort D, Hardy W and Muller W: Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. *Mol. Cell. Biol.* 14:7068-7077, 1994.



DEPARTMENT OF THE ARMY

US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

28 July 03

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl

PHYLLIS M. RINEHART

Deputy Chief of Staff for
Information Management

ADB233865	ADB264750
ADB265530	ADB282776
ADB244706	ADB286264
ADB285843	ADB260563
ADB240902	ADB277918
ADB264038	ADB286365
ADB285885	ADB275327
ADB274458	ADB286736
ADB285735	ADB286137
ADB286597	ADB286146
ADB285707	ADB286100
ADB274521	ADB286266
ADB259955	ADB286308
ADB274793	ADB285832
ADB285914	
ADB260288	
ADB254419	
ADB282347	
ADB286860	
ADB262052	
ADB286348	
ADB264839	
ADB275123	
ADB286590	
ADB264002	
ADB281670	
ADB281622	
ADB263720	
ADB285876	
ADB262660	
ADB282191	
ADB283518	
ADB285797	
ADB269339	
ADB264584	
ADB282777	
ADB286185	
ADB262261	
ADB282896	
ADB286247	
ADB286127	
ADB274629	
ADB284370	
ADB264652	
ADB281790	
ADB286578	